Printer Friendly

NORTH AMERICAN BIOLOGICALS LAUNCHES EXPANSION PROGRAM TO MEET RISING DEMAND FOR PLASMA PRODUCTS

 NORTH AMERICAN BIOLOGICALS LAUNCHES EXPANSION PROGRAM
 TO MEET RISING DEMAND FOR PLASMA PRODUCTS
 MIAMI, March 9 /PRNewswire/ -- North American Biologicals, Inc. ("NABI") (NASDAQ: NBIO) today announced a major corporate expansion program designed to increase the company's plasma product capacity by more than 20 percent over the next six months. The company's plans are in response to the upswing in worldwide demand for these health care products, evidenced in recent months by growing orders from NABI's client base.
 NABI management stated that the expansion program will include the establishment of at least one new collection center, the acquisition and planned increase in output of existing centers now operating under contract to the company, and other potential acquisitions currently under consideration. Construction began this month on a new center in Norman, Okla., adjacent to the campus of the University of Oklahoma. Later this month, NABI expects to assume control of two additional FDA-licensed centers, in Racine and Beloit, Wis. which are currently under contract to NABI.
 NABI attributed the growth in plasma demand to several factors, including the resolution by regulatory agencies of certain issues pertaining to the testing of plasma, and the increasing use of hyperimmune plasmas to treat a variety of immunological disorders, including hepatitis and AIDS.
 "Worldwide market trends for plasma products are extremely favorable to NABI," said David J. Gury, president of NABI. "Not only is there an increase in the absolute quantity of plasma required for a wide range of products valued at $3.4 billion per year, but there is also an intensifying need for higher quality plasma to meet more stringent regulatory requirements. NABI is well positioned in both respects, in that we are the largest independent supplier of plasma in the world, and we offer only the highest quality products," Gury added.
 North American Biologicals, Inc., headquartered in Miami, Fla., is the world's largest independent provider of human blood plasma elements to the health care industry, the largest AIDS screening laboratory in the United States, and the leading supplier of control products used to ensure accuracy in blood testing laboratories. The company currently operates 38 collection centers in 17 states.
 -0- 3/9/92
 /CONTACT: David J. Gury, or Alfred J. Fernandez of North American Biologicals, Inc. 305-628-0080; or Marcia Kean or Lori Martin of Feinstein Partners Inc., 617-577-8110, for North American Biologicals/ CO: North American Biological, Inc. ST: Florida IN: MTC SU:


TM-DH -- NE004 -- 6271 03/09/92 09:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:408
Previous Article:VICORP RESTAURANTS REPORTS RECORD OPERATING EARNINGS
Next Article:CYTOGEN AND CYTORAD: UNDERWRITERS EXERCISE OVER-ALLOTMENT OPTION
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS AWARDED $9 MILLION IN FEDERAL CONTRACTS FOR AIDS SCREENING AND OTHER BLOOD TESTING AND PRODUCTS
NORTH AMERICAN BIOLOGICALS GAINS $2.5 MILLION IN ORDERS FOR HYPERIMMUNE PLASMA PRODUCTS FROM NEW CUSTOMER
NORTH AMERICAN BIOLOGICALS REPORTS FIRST QUARTER 1992 RESULTS
NORTH AMERICAN BIOLOGICALS INCREASES PLASMA COLLECTION CAPABILITIES
NORTH AMERICAN BIOLOGICALS, INC. AWARDED $45 MILLION EUROPEAN CONTRACT: PLASMA ORDER IS LARGEST IN NABI'S HISTORY
NORTH AMERICAN BIOLOGICALS RECEIVES FDA LICENSE FOR NEW BIOMEDICAL CENTER - $1.7 MILLION IN PLASMA SHIPMENTS FROM OKLAHOMA SITE UNDERWAY
NORTH AMERICAN BIOLOGICALS, INC. LAUNCHES EUROPEAN OPERATIONS WITH ACQUISITION OF GERMAN PLASMA FACILITIES
Baxter to Further Increase Manufacturing Capacity for Therapeutic Proteins.
CSC Wins $19.6 Million Contract for Advanced Development of Chemical Nerve Agent Treatment; CSC's DVC Teams With Baxter Healthcare Corporation to...
The American National Red Cross Affirms Its Ongoing Support of Joint Projects with ProMetic.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters